Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus abiraterone acetate and prednisone vs abiraterone acetate and prednisone in HRR gene-mutated metastatic castration-sensitive prostate cancer
2023-506365-64-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in prostate adenocarcinoma comparing Niraparib + abiraterone acetate + prednisone with Placebo + abiraterone acetate + prednisone (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
niraparib
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2023-506365-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506365-64-00.